Recently, DASAN Pharmaceutical’s hypertension treatment drug for export,“DASAN Telmisartan Amlodipine Tablets80/10mg”received approval from the Korean Ministry of Food and Drug Safety. This marks the first export drug approval in about three years since December 2022, expanding its export hypertension product line to nine products, covering telmisartan monotherapy and combination products with amlodipine or hydrochlorothiazide, further enriching its product portfolio.

Prior to the approval of “DASAN Telmisartan Amlodipine Tablets 80/10mg,” DASAN Pharmaceutical already had eight products for the control of essential hypertension. These eight products consist of two telmisartan monotherapies, three combination products with valsartan and amlodipine, and three combination products with telmisartan and hydrochlorothiazide. Notably, with this approval, DASAN has added a combination product containing telmisartan and amlodipine. Although the company already has a combination product with the same ingredients in the domestic Korean market, this marks its first export license.

This move is part of DASAN Pharmaceutical’s expansion into the global market. In addition to increasing its export products, the company is also building a joint venture pharmaceutical manufacturing plant in China, leaping forward as a global Contract Development and Manufacturing Organization (CDMO) enterprise.

DASAN Pharmaceutical signed an agreement with the Chinese company Anhui Heyida Pharmaceutical to build a factory that will begin producing drugs next year. DASAN plans to use the joint venture factory located in the National Industrial Development Zone of Chuzhou High-tech Zone, Tianchang City, Chuzhou City, Anhui Province, China, as a bridgehead to expand its global business. In this regard, DASAN’s CEO, Ryu Hyung-sun, stated in an interview with Medipana News earlier this year that the company would leverage its Contract Manufacturing Organization (CMO) experience to create opportunities in the growing global CDMO market, covering both synthetic and biopharmaceuticals.

DASAN Pharmaceutical plans to use China’s Marketing Authorization Holder (MAH) system to develop its CDMO business. For pharmaceutical companies aiming to enter the Chinese market, DASAN will leverage its joint venture factory and specialized technology to provide comprehensive CDMO solutions covering production and supply.

Through seminars, briefings, and other events, DASAN Pharmaceutical has been introducing the application of the MAH system to Korean pharmaceutical and biotech companies. The company also plans to participate in “CPhI China 2026” in Shanghai next year to publicly showcase its production line in the Chinese factory.